Page 3 - Aurobindo Pharma

These 5 pharma stocks can fall up to 12% as technical charts flag caution

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

Stocks to Watch, May 27: Aurobindo Pharma, Nazara Tech, IndiGo, Lupin, TCS

Stocks to Watch on Tuesday: Aurobindo Pharma, Nazara Tech, IndiGo, Lupin, TCS, PG Electroplast and Sagility India are among the stocks to watch today, May 27, 2025

Aurobindo Pharma Q4 results: Profit dips to ₹903 cr, revenue up 11%

Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025. The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24. Its total revenue from operations stood at Rs 8,382 crore for the fourth quarter compared to Rs 7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing. For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24. The total revenue from operations rose to Rs 31,724 crore last fiscal from Rs 29,002 crore in 2023-24. "We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said. The drug firm's European operation

Aurobindo Pharma Q4 net dips 0.5%, revenue up 10.5% to Rs 8,382 cr

US and Europe markets drive growth as company posts flat profit for Q4 FY25; files 9 ANDAs and launches 5 new products during the quarter

Aurobindo Pharma Q4 PAT falls marginally to ₹903 cr, revenue up 10%

Aurobindo Pharma posts flat Q4 net profit of ₹903 crore while revenue rises 10.6% YoY to ₹8,382 crore; Europe, ARV segments show strong growth amid R&D focus

Q4 results today: GIC, Aurobindo Pharma, Bluedart, Gillette on May 26

Q4 FY25 company results today: Vadilal Industries, Sumitomo Chemical, Sundaram Finance, Bayer Cropscience will be among 221 companies to post earnings reports for the January-March quarter

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

Aurobindo Pharma in focus: Why has the stock gained 3% in trade today?

Aurobindo Pharma Ltd share price: The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to manufacture and market Dasatinib tablets

5 midcap stocks ideas that can deliver up to 24% returns in the short-term

Aurobindo Pharma, IPCA Labs, Oil India, Mazagon Dock and GIC RE are the 5 midcap stocks that can potentially surge up to 24% from present levels, suggests technical charts.

Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug

Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Aurobindo Pharma to begin supplies to Europe from China plant in April

Aurobindo Pharma will commence supplies to Europe from its China facility from April onwards, according to Chief Financial Officer Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production. "The China plant will start billing sometime in the month of April, mainly to the European markets," Subramanian told analysts in a call. The company has received European regulatory approvals and can initiate product supply to the market, he added. "We are in the process of getting it (in China) and after that there may be an inspection for the US (market) also," Subramanian said. The company expects good traction coming out of the China plant over the next 2-3 years, he noted. When asked about revenue projections, Subramanian stated: "This being the first year, we may not like to, but certainly I see a significant revenue coming up in two to three years' time." On a query regarding the ..

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Aurobindo Pharma Q3FY25 results: PAT falls 10% to Rs 845.56 crore

Company board approves purchase of 80 per cent share in step-down subsidiary Tergene Biotech

5 stocks that can benefit from China + 1 strategy; here's how to trade them

Stocks from manufacturing and outsourcing hubs stand to benefit under the China Plus One strategy; Technical chart shows that shares of Amber, Aurobindo and others can rally up to 33% from here on.

Here's why Aurobindo Pharma gained 2% in trade on December 23; details here

Aurobindo Pharma share rose after it announced that CuraTeQ Biologics s.r.o., a step-down subsidiary of company, has obtained marketing authorisation from UK's MHRA for Bevqolva

Stocks to Watch, Dec 23: JBM Auto, Sterling & Wilson, Aurobindo Pharma, L&T

Stocks to Watch, December 23, 2024: JBM Auto's subsidiary has been awarded a Rs 1,800 crore contract by Ahmedabad BRTS for the supply of 343 electric buses

Aurobindo Pharma, Glenmark, and Zydus recall products in US over mfg issues

Drug makers Aurobindo Pharma, Glenmark and Zydus are recalling products in the US market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), Aurobindo Pharma USA Inc, a subsidiary of Hyderabad-based drug maker, is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths. The New Jersey-based firm is recalling the product due to "GMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit," the US health regulator said. The company initiated the Class II recall on November 7 this year. Cinacalcet tablets are used to treat hyperparathyroidism. Similarly, a US-based subsidiary of Glenmark Pharmaceuticals is recalling around 90,000 bottles of Diltiazem Hydrochloride extended-release capsules (multiple strengths) in the US market. New Jersey-based Glenmark Pharmaceuticals Inc, USA is recalling the affected lot of Diltiazem Hydrochloride ...